OBSTETRIC-FETAL PHARMACOLOGY RESEARCH UNITS NETWORK

产胎药理学研究单位网络

基本信息

批准号：
8172648
负责人：
GARY D HANKINS
金额：
$ 0.32万
依托单位：
TEXAS BIOMEDICAL RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-05-01 至 2011-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8172648
关键词：
Aneuploidy Aromatase Caring Chronic Clinic Clinical Trials Computer Retrieval of Information on Scientific Projects Database Diabetes Mellitus Discipline of obstetrics Doctor of Philosophy Drug Kinetics Enzymes Evaluation Funding Genetic Polymorphism Grant Head Human Human Chorionic Gonadotropin Hypoglycemic Agents In Vitro Institution Investigation Laboratories Ligands Lobule Magnesium Sulfate Maternal Physiology Maternal and Child Health Mediating Medical Metabolic Multicenter Trials Neonatal Opiates Outcome Patient Recruitments Perfusion Pharmaceutical Preparations Pharmacology Placenta Pregnancy Pregnancy Proteins Pregnant Women Preparation Protocols documentation Research Research Personnel Resources Risk Second Pregnancy Trimester Source System Texas Tissues Ultrasonography United States National Institutes of Health Universities Vagina experience fetal fetal medicine in vivo member placental transfer programs receptor response trophoblast

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The University of Texas Medical Branch (UTMB) has the capability to participate actively as a member of the Obstetric-Fetal Pharmacology Research Units (OPRU) Network. Gary Hankins, MD, as PI, is responsible for the proposed clinical trial on the use of hypoglycemic drugs in the treatment of diabetes during pregnancy. He has extensive experience within several NIH multicenter trials, eg, First and Second Trimester Evaluation of Risk of Aneuploidy (FASTER), Beneficial Effects of Antenatal Magnesium Sulfate Study (BEAM), and the Vaginal Ultrasound Cerclage Trial. Dr. Hankins has achieved successful patient recruitment and retention by involvement with UTMB's Regional Maternal & Child Health Program (RMCHP). All RMCHP clinics follow protocols established by the Maternal-Fetal Medicine division, headed by Dr. Hankins. Over 12,000 pregnant women are cared for annually within the RMCHP clinic system, approximately 7,000 of whom deliver at UTMB. The Pharmacology/Pharmacokinetics (PK) Co-Investigator, Mahmoud S. Ahmed, PhD, has over 25 years of expertise in utilizing human placenta and derived preparations in his investigations. Dr. Ahmed is a laboratory-pioneered investigator in placental receptors, their natural ligands and mediated responses, as well as the mechanism of hCG release from trophoblast tissue. They investigated the effects of in vitro and in vivo chronic administration of opiates on placental physiology and maternal-neonatal outcome. Utilizing dual perfusion of placental lobule, they demonstrated the influence of efflux protein and placental metabolic [enzymes on the PK for placental transfer of opiates. They identified placental aromatase as a drug-metabolizing enzyme and are investigating its polymorphism.

该副本是利用众多研究子项目之一由NIH/NCRR资助的中心赠款提供的资源。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构是对于中心，这不一定是调查员的机构。德克萨斯大学医学分支机构（UTMB）有能力积极参与产科狂药理学研究单元（OPRU）网络的成员。医学博士Gary Hankins作为PI，负责拟议的临床试验，该试验在怀孕期间使用降血糖药物治疗糖尿病。他在几项NIH多中心试验中拥有丰富的经验，例如，孕产生硫酸镁研究（BEAM）和阴道超声CERCLAGE试验的非整倍性风险（更快），有益的效果。 Hankins博士通过参与UTMB的区域孕产妇健康计划（RMCHP）实现了成功的患者招聘和保留。所有RMCHP诊所均遵循由汉金斯博士领导的母亲 - 福利医学部建立的方案。每年在RMCHP诊所系统中每年都有12,000多名孕妇的照顾，其中约有7,000名在UTMB交付。药理学/药代动力学（PK）共同投资者Mahmoud S. Ahmed博士在他的调查中使用人体胎盘和衍生准备工作有25年以上的专业知识。艾哈迈德（Ahmed）博士是胎盘受体，天然配体和介导的反应以及HCG从滋养细胞组织中释放的机制的实验室偏位研究者。他们调查了鸦片剂的体外和体内长期给药对胎盘生理和孕产妇 - 神经结局的影响。利用胎盘小叶的双重灌注，他们证明了外排蛋白和胎盘代谢[PK上的酶以用于胎盘转移阿片类药物的影响。他们将胎盘芳香酶确定为一种药物代谢酶，并正在研究其多态性。